Diagnosis of Endocrine Dysfunctions in Covid-19

Study Overview
=================
Brief Summary
-----------------
As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells. The renin aldosterone angiostensin system (RAAS) has known effects in the lungs: some receptors are pro-inflammatory, others are anti-inflammatory. Thus the deregulation of the RAAS induced by the SARS-CoV-2 could explain the inflammatory response of Covid-19 infection and be a modulator of the severity of its course. Furthermore, the SARS 2003 experience suggests that there may be others endocrine involvment, particularly an failure on the hypothalamus-pituitary and adrenal axis. Indeeed, cases of hypocorticism and hypothyroidism of central origin were described. Altogether, the endocrine system might play a role both in the pathophysiology of Covid-19 infection and in the activity and severity of the disease. In this study, the investigators proposed to explore endocrine functions on biological samples in a series of patients admitted for Covid-19 in our clinic.

Official Title
-----------------
Diagnosis of Endocrine Dysfunctions in Covid-19 : Explorations of the Plasma Renin and Aldosterone Levels in Patients With Covid-19 Infection.

Conditions
-----------------
Covid 19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Patients with Covid-19 diagnosis and hospitalized in our clinic Exclusion criteria: - Minor patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma aldosterone levels | Plasma aldosterone levels | 1 day (at inclusion) | 
| Plasma renin levels | Plasma renin levels | 1 day (at inclusion) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| covid-19 infection severity | covid-19 infection severity : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death). | 1 day (at inclusion) | 
| Maximum severity of Covid-19 infection | Maximum severity of Covid-19 infection using a seven-category ordinal scale at at the end of hospitalization : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death). | 1 day (at inclusion) | 
| Plasma aldosterone level | Plasma aldosterone level | 1 day (at the end of hospitalization) | 
| Plasma ACTH level | Plasma ACTH level | 1 day (at the end of hospitalization) | 
| Plasma cortisol level | Plasma cortisol level | 1 day (at inclusion) | 
| Plasma cortisol level | Plasma cortisol level | 1 day (at the end of hospitalization) | 
| Plasma T3l level | Plasma T3l level | 1 day (at the end of hospitalization) | 
| Plasma T3l level | Plasma T3l level | 1 day (at inclusion) | 
| Plasma ACTH level | Plasma ACTH level | 1 day (at inclusion) | 
| Plasma LH level | Plasma LH level | 1 day (at inclusion) | 
| Plasma LH level | Plasma LH level | 1 day (at the end of hospitalization) | 
| Plasma DHEA level | Plasma DHEA level | 1 day (at the end of hospitalization) | 
| Plasma DHEA level | Plasma DHEA level | 1 day (at inclusion) | 
| Plasma estradiol (female) or testosterone (male) level | Plasma estradiol (female) or testosterone (male) level | 1 day (at the end of hospitalization) | 
| Plasma estradiol (female) or testosterone (male) level | Plasma estradiol (female) or testosterone (male) level | 1 day (at inclusion) | 
| Plasma FSH level | Plasma FSH level | 1 day (at the end of hospitalization) | 
| Plasma FSH level | Plasma FSH level | 1 day (at inclusion) | 
| type of treatments | type of treatments | 1 day | 
| Clinical characteristics | Clinical characteristics extracted from electronic medical | 1 day | 
| radiological characteristics | radiological characteristics : quantification of the percentage of lesional damage to the pulmonary parenchyma | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid-19, Renin Angiotensin Aldosterone System, Hormon disorders